TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
出版年份 2021 全文链接
标题
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
作者
关键词
-
出版物
JOURNAL OF CLINICAL ONCOLOGY
Volume -, Issue -, Pages JCO.20.03489
出版商
American Society of Clinical Oncology (ASCO)
发表日期
2021-05-01
DOI
10.1200/jco.20.03489
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mature results from EV-101: A phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC).
- (2019) Jonathan E. Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study.
- (2019) Scott T. Tagawa et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
- (2019) Y Fradet et al. ANNALS OF ONCOLOGY
- Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results
- (2019) Padmanee Sharma et al. JOURNAL OF CLINICAL ONCOLOGY
- Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
- (2019) Jonathan E. Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
- (2019) Yohann Loriot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
- (2018) Manish R Patel et al. LANCET ONCOLOGY
- Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies
- (2018) Pedro C. Barata et al. Targeted Oncology
- The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
- (2018) David M. Goldenberg et al. Oncotarget
- A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany
- (2018) Günter Niegisch et al. Journal of Cancer
- Cctg BL12: Randomized phase II trial comparing nab-paclitaxel (Nab-P) to paclitaxel (P) in patients (pts) with advanced urothelial cancer progressing on or after a platinum containing regimen (NCT02033993).
- (2018) Srikala S. Sridhar et al. JOURNAL OF CLINICAL ONCOLOGY
- Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes
- (2018) Petros Grivas et al. CANCER
- Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan
- (2017) Rebecca Suk Heist et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
- (2017) Daniel P Petrylak et al. LANCET
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer
- (2017) Chiara Avellini et al. Oncotarget
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
- (2017) Thomas Powles et al. JAMA Oncology
- Sacituzumab Govitecan, a Novel Antibody–Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma
- (2016) Bishoy Faltas et al. Clinical Genitourinary Cancer
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis
- (2015) D. Raggi et al. ANNALS OF ONCOLOGY
- Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
- (2015) Thomas M. Cardillo et al. BIOCONJUGATE CHEMISTRY
- First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
- (2015) A. N. Starodub et al. CLINICAL CANCER RESEARCH
- Third-Line Chemotherapy for Metastatic Urothelial Cancer
- (2015) Giuseppe Di Lorenzo et al. MEDICINE
- The Safety and Efficacy of Single-Agent Pemetrexed in Platinum-Resistant Advanced Urothelial Carcinoma: A Large Single-Institution Experience
- (2015) R. M. Bambury et al. ONCOLOGIST
- Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
- (2015) David M. Goldenberg et al. Oncotarget
- Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via -catenin signaling
- (2012) T. Stoyanova et al. GENES & DEVELOPMENT
- Upregulation of Trop-2 quantitatively stimulates human cancer growth
- (2012) M Trerotola et al. ONCOGENE
- Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys
- (2011) T. M. Cardillo et al. CLINICAL CANCER RESEARCH
- Expression of Trop2 Cell Surface Glycoprotein in Normal and Tumor Tissues
- (2011) Lara P. Stepan et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens
- (2010) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
- Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer
- (2009) Y. J. Fang et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
- (2009) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
- High expression of TROP2 correlates with poor prognosis in pancreatic cancer
- (2008) D Fong et al. BRITISH JOURNAL OF CANCER
- TROP2 expression as prognostic marker for gastric carcinoma
- (2008) G Muhlmann et al. JOURNAL OF CLINICAL PATHOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search